← Back to Screener
enGene Therapeutics Inc. Warrants (ENGNW)
Price$0.28
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-103.81%
Price vs S&P 500 (4W)-92.57%
VGM Score23.42
All Metrics
Price vs S&P 500 (YTD)-99.62%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.02M
52-Week High$4.20
26-Week Price Return-88.71%
13-Week Price Return-86.73%
3-Month Return Std Dev284.08%
Year-to-Date Return-90.54%
5-Day Price Return8.07%
Month-to-Date Return-3.45%
Price vs S&P 500 (13W)-97.31%
Beta1.29x
52-Week Low$0.11
mGradeD
vgmGradeD
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENGNWenGene Therapeutics Inc. Warrants | — | — | D | $0.28 |
| AMGNAmgen Inc | C | C | C | $338.22 |
| GILDGilead Sciences Inc | C | B | C | $128.99 |
| ARGXargenx SE American Depositary Shares | D | A | B | $813.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $155.99 |
| BIIBBiogen Inc. Common Stock | B | D | C | $195.96 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.45 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $165.11 |
| EXELExelixis Inc | C | B | B | $51.60 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $301.82 |
About
enGene Holdings is a clinical-stage biotechnology company developing non-viral gene therapies using its proprietary DDX gene delivery platform, which enables localized administration of genetic material to mucosal tissues and other organs. The company is initially targeting non-muscle invasive bladder cancer and is positioned to expand into additional disease areas with significant unmet clinical needs.